A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer - ND
- Conditions
- Her2 overexpressed, early stage breast cancer (adjuvant treatmente stage).MedDRA version: 12.0Level: LLTClassification code 10006173Term: Breast adenocarcinoma
- Registration Number
- EUCTR2008-007345-31-IT
- Lead Sponsor
- Wyeth Research, Division of Wyeth Pharmaceuticals, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 2840
1.Subjects must have histologically confirmed primary adenocarcinoma of the breast that is erbB-2 positive by one of the following assays, performed locally: o Fluorescence in situ hybridization (FISH) or silver in situ hybridization (SISH) must show gene amplification (defined as >2.2), OR o Chromogenic in situ hybridization (CISH) show gene amplification according to the manufacturer`s kit instructions, OR o Immunohistochemistry (IHC) assay must show strong positive (ie, 3+ = >30% of invasive tumor cells) staining score. 2. Primary tumor ER/PgR status must be known before study entry. 3. Subjects must have completed a course of prior adjuvant trastuzumab. If less than 12 months of trastuzumab have been given, at least 8 prior doses of weekly trastuzumab, or at least 3 prior doses of trastuzumab given every 3 weeks, must have been administered and it must be specified that the subject is either not eligible or unable to receive further adjuvant trastuzumab. The last dose of trastuzumab must have been given >2 weeks and <2 years from randomization. 4. Have a diagnosis of stage 1 through stage 3c primary breast cancer according to the American Joint Committee on Cancer (sixth edition) staging criteria for breast cancer and meet one of the following criteria: o Axillary node-positive disease OR node-negative disease with a primary tumor greater than or equal to 1.0 cm in greatest diameter. (For clarification, isolated tumor cells are considered pN0 and micrometastases are considered pN1.) o Node-negative disease is defined as negative sentinel node biopsy OR no positive lymph nodes found among 6 ancillary nodes examined on axillary node dissection OR status after axillary radiotherapy for sterilization if clinically evaluated as cN0. 5. Adequately treated primary breast cancer with surgery, as defined by prior mastectomy OR lumpectomy, with margins clear of invasive carcinoma and DCIS. Subjects with positive sentinel node biopsies must have subsequent axillary dissection to be eligible; negative sentinel node biopsies require no more axillary surgery for eligibility. 6. Completed treatment with a neoadjuvant or adjuvant chemotherapy regimen containing either an anthracycline or a taxane or any cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) regimen. 7. Clinical and radiologic assessments that are negative for local or regional recurrence of disease or metastatic disease at the time of study entry, including: o Bone scan; required only if alkaline phosphatase (ALP) is ≥2 x upper limit of normal (ULN) and/or there are symptoms of metastatic bone disease. A confirmatory imaging study is required if the results from the bone scan are questionable. o Computed tomography (CT) or ultrasound scan of the abdomen; required only if aspartate transaminase (AST)/alanine transaminase (ALT) or ALP is ≥2 x ULN, unless the elevation is in the bone fraction. o Chest radiograph. 8. Negative bilateral mammogram (or unilateral mammogram of the remaining breast if unilateral total mastectomy was performed) within 12 months before study entry. Mammogram not indicated in case of bilateral total mastectomy. 9. Subjects with bilateral breast cancers are eligible only if their primary cancers occurred synchronously (ie, diagnosed at the same time [occurring within 6 months of each other]). One or both tumors need to be erbB-2 positive. One could be negative. 10. Female subjects aged 18 years or older. 11. Su
1. Clinical or radiologic evidence of local or regional recurrence of disease or metastatic disease at the time of study entry. 2. Currently receiving chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer. 3. Any prior mediastinal irradiation except internal mammary node irradiation for the present breast cancer. 4. Metachronous invasive or DCIS breast cancer (ie, primary breast cancers diagnosed at different times [diagnosed greater than 6 months apart from each other]). 5. Prior therapy with an erbB-1 and/or erbB-2 inhibitor other than trastuzumab. 6. Received any investigational agent within 14 days or 5 half-lives, whichever is longer, before administration of the first dose of investigational product. 7. Pregnant or breastfeeding women. 8. Subjects with a concurrently active second malignancy, other than adequately treated nonmelanoma skin cancers, in situ melanoma, or in situ cervical cancer. Subjects with other nonmammary malignancies must have been disease free for at least 5 years. 9. Subjects with unstable angina, congestive heart failure (New York Heart Association class II, III, or IV) (including individuals who currently use digitalis, beta-blockers, or calcium channel blockers specifically for congestive heart failure), ventricular arrhythmia requiring medical therapy, or with a history of myocardial infarction within 12 months. 10. Subjects with active unresolved infections. 11. Inability or unwillingness to swallow tablets. 12. Significant chronic gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn?s disease, ulcerative colitis, malabsorption, or grade ≥2 diarrhea of any etiology at baseline). 13. QTc interval >0.45 seconds or known history of QTc prolongation or torsades de pointes. 14. History of idiopathic ventricular tachycardia or ventricular fibrillation. 15. Subjects with a psychiatric illness that would prevent them from understanding the nature of the investigational therapy and complying with protocol requirements. 16. Any major concurrent illness or medical condition that, in the investigator?s judgment, will substantially increase the risk associated with the subject?s participation in and completion of the study. 17. Known or suspected allergy to neratinib or other compounds related to these classes of medication.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method